Indian generics makers are on a roll. Yesterday, a Ranbaxy-Ipca Laboratories unit got the OK to make generic Metformin; today, a Sun Pharmaceuticals subsidiary won a tentative FDA for its version of Prandin, a type 2 diabetes drug originally made by Novo Nordisk.
Caraco Pharmaceutical Laboratories, based in Detroit, says it's first out of the chute with generic repaglinide, and it's hoping for 180-day marketing exclusivity. The approval is contingent on Caraco's resolution of any patent issues with Novo Nordisk, now under litigation.
- read the report from the Detroit Free Press
Patent 'cliff' looms for Big Pharma. Report
Indian court spurns Novartis on patent challenge. Report
Generic competition slashes prices. Report
India's biotech future is bright. Report